Showing 4351-4360 of 6948 results for "".
- IEC Session Highlights AA/AD Connectionhttps://practicaldermatology.com/news/IEC-Session-Highlights-AA-AD-Connection/2471516/The International Eczema Council (IEC) meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, was a crossover event. The IEC partnered with both the National Eczema Association (NEA) and National Alopecia Areata Foundation (NAAF) to present
- Novartis to Present CSU, HS Data for Remibrutinib, Secukinumabhttps://practicaldermatology.com/news/Novartis-Present-CSU-HS-Data-Remibrutinib-Secukinumab/2471383/Novartis announced it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting and the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organizatio
- Study Shows Oral Minoxidil Improves Patient Outcomes for Hair Losshttps://practicaldermatology.com/news/study-shows-oral-minoxidil-improves-patient-outcomes-for-hair-loss/2471041/New research in the Journal of Drugs in Dermatology shows oral minoxidil outperforming topical formulations in terms of patient adherence, satisfaction, and ease of use, without significantly increasing systemic side effects. Researchers on the study studied 50 patients using eith
- Analysis: FDA Approvals Highlight Disparities in Oncology Outcomes by Ancestryhttps://practicaldermatology.com/news/analysis-fda-approvals-highlight-disparities-oncology-outcomes-ancestry/2470889/Patients of African ancestry remain underrepresented in eligibility for biomarker-driven precision oncology therapies, according to a new study in JAMA Dermatology. The retrospective analysis of 59,433 patients with solid cancers looked at genetic sequencing data from MSK-IMPACT a
- Higher WWI Linked to Increased Mortality Rates in Psoriasis Patientshttps://practicaldermatology.com/news/higher-wwi-linked-increased-mortality-rates-psoriasis-patients/2470869/New research indicates a strong positive correlation between weight-adjusted waist index (WWI) and all-cause mortality in psoriasis patients. Researchers at Wenzhou Medical University in China published “Weight-Adjusted Waist Index, Psoriasis, and All-Cause Mortality: Findings from the NHA
- JAK Inhibitors May Help Eosinophilic Colitis in AD Patientshttps://practicaldermatology.com/news/jak-inhibitors-may-help-eosinophilic-colitis-ad-patients/2468766/Janus kinase (JAK) inhibitors show promise in managing eosinophilic colitis (EoC) in adults with coexisting atopic dermatitis (AD), according to results from a novel case series. Researchers publishing in The Clinical Journal of Gastroenterology presented four cases of adult EoC s
- Study Highlights Gaps in Fitzpatrick Skin Type Determinationhttps://practicaldermatology.com/news/study-highlights-gaps-fitzpatrick-skin-type-determination/2468709/New research published in The Journal of Clinical and Aesthetic Dermatology evaluated concordance between self-assessed and provider-determined Fitzpatrick skin types (FSTs). Study researchers conducted the analysis of 472 patients attending a dermatology practice and included dat
- Study Links Psoriasis Severity to Increased Heart Disease Riskhttps://practicaldermatology.com/news/study-links-psoriasis-severity-increased-heart-disease-risk/2468660/Psoriasis severity is associated with increased cardiovascular risk, according to new research, with systemic inflammation functioning as a key mediator. Data from two cohorts—the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative (PACI) and the Stockholm Psoriasis Cohort (SP
- Analyses: Ruxolitinib Cream Reduces AD Symptom Burden in 12 Hourshttps://practicaldermatology.com/news/analyses-ruxolitinib-cream-reduces-ad-symptom-burden-12-hours/2468615/Ruxolitinib cream significantly reduced skin pain and improved patient-reported outcomes (PROs) in individuals with mild-to-moderate atopic dermatitis (AD), with improvements sustained over 52 weeks, according to data from the TRuE-AD1 and TRuE-AD2 studies. Researchers the results publishi
- EADV Presentation to Highlight New IL-13/IL-31 Bispecific Antibodyhttps://practicaldermatology.com/news/eadv-presentation-highlight-new-il-13il-31-bispecific-antibody/2468228/Data from a preclinical study of ZL-1503, an IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (EADV) 2024 taking place September 25-28 in Amsterdam, Ne